At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Lyrica 300 mg +1 moredrug
Likely dose
Lyrica 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.
In Brief
A clinical study evaluating Lyrica 300 mg and Placebo for Oropharyngeal Cancer and Squamous Cell Carcinoma to the Head and Neck. Completed, enrolled 20 participants across 1 site.
Detailed Summary
To assess the efficacy of pregabalin in the management of mucositis pain in patients receiving radiotherapy to the head and neck. Eligible study subjects will be enrolled among those being treated for oropharyngeal cancer with definitive chemotherapy and radiation therapy (photons) to the head and neck in the Department of Radiation Oncology at the University of Pennsylvania.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMay 2014
First PostedOct 2014
Primary CompletionApr 2018
TodayJul 2026
First PostedOct 29, 2014
Enrollment StartMay 1, 2014
Primary CompletionApr 1, 2018
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 11.7 years ago
Interventions
Lyrica 300 mgdrug
Lyrica 300 mg per day
Placebodrug